Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid Leukemia

Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid Leukemia

Constitutive activation of FLT3 by ITD mutations is one of the most common genetic aberrations in AML, present in ~1/3 of cases. Patients harboring <i>FLT3</i>-ITD display worse clinical outcomes. The integration and advancement of FLT3 TKI in AML treatment provided significant therapeut...

Full description

Bibliographic Details
Main Authors:	Javier Bregante, Anna Schönbichler, Daniel Pölöske, Lina Degenfeld-Schonburg, Garazi Monzó Contreras, Emir Hadzijusufovic, Elvin D. de Araujo, Peter Valent, Richard Moriggl, Anna Orlova
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Cancers
Subjects:	acute myeloid leukemia tyrosine kinase inhibitor FMS-like tyrosine kinase 3 targeted therapy ponatinib cabozantinib
Online Access:	https://www.mdpi.com/2072-6694/13/24/6181

Similar Items

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
by: Bai‐Liang He, et al.
Published: (2020-04-01)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
by: Jeffrey Sum-Lung Wong, et al.
Published: (2021-04-01)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
by: Riad El Fakih, et al.
Published: (2018-01-01)

FLT3-ITD Incidence and FLT-D835 Mutations in Acute Myeloid Leukemia Patients with Normal Karyotype in Morocco: A Preliminary Study
by: Hind Dehbi, et al.
Published: (2013-01-01)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
by: Shano Naseem, et al.
Published: (2021-01-01)

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia
by: Moo-Kon Song, et al.
Published: (2022-10-01)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
by: Pashtoon M. Kasi, et al.
Published: (2016-01-01)

Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study
by: Ahmed M. Abbas, et al.
Published: (2018-07-01)

Relation between FMS-like tyrosine kinase 3 factor and hematological parameter in acute lymphoblastic leukemia patients by flow cytometry
by: Zainab Samir Al-Ali, et al.
Published: (2022-01-01)

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01)

FLT3 inhibitors in acute myeloid leukemia
by: Mei Wu, et al.
Published: (2018-12-01)

Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML
by: Maya Graham Pedersen, et al.
Published: (2022-09-01)

Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia
by: Freidoon Solhjoo, et al.
Published: (2018-10-01)

MIF Increases sFLT1 Expression in Early Uncomplicated Pregnancy and Preeclampsia
by: Qing Yong, et al.
Published: (2023-06-01)

Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia
by: Ping Tang, et al.
Published: (2017-01-01)

Probable ponatinib-induced papilledema in a patient with acute lymphocytic leukemia
by: Jared A. Moon, et al.
Published: (2023-12-01)

Tyrosine kinase inhibitor-loaded biomimetic nanoparticles as a treatment for osteosarcoma
by: Federica Giordano, et al.
Published: (2022-12-01)

Ponatinib modulates the metabolic profile of obese mice by inhibiting adipose tissue macrophage inflammation
by: Zhuomiao Lin, et al.
Published: (2022-11-01)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
by: Mario Tiribelli, et al.
Published: (2019-08-01)

Ponatinib-associated panniculitis: Case report and review of the literature
by: Daniel Antwi-Amoabeng, et al.
Published: (2021-01-01)

Analysis of Methyldopa Therapy on sFlt-1 Antiangiogenic Levels in Patients with Severe Preeclampsia
by: Teri Wina Herwati, et al.
Published: (2018-04-01)

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)
by: Tarini Prasad Sahoo, et al.
Published: (2023-08-01)

Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
by: Stefania Kokkali, et al.
Published: (2023-01-01)

Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications
by: Eleonora Lauricella, et al.
Published: (2022-08-01)

15,16-Dihydrotanshinone I inhibits the proliferation of MV4-11 by means of apoptosis via antagonizing FLT3-ITD/STAT5/Mcl-1 pathway
by: Mansheng Luo, et al.
Published: (2023-01-01)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
by: Motoki Eguchi, et al.
Published: (2020-07-01)

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
by: Jessica K. Altman, et al.
Published: (2021-02-01)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
by: Srdan Verstovsek, et al.
Published: (2016-12-01)

Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
by: Varvara Maiorova, et al.
Published: (2023-04-01)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu
Published: (2013-09-01)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
by: Linnea Højer Wang, et al.
Published: (2023-01-01)

A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy
by: Georgia Geller, et al.
Published: (2017-09-01)

Atypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report
by: Anannya Patwari, et al.
Published: (2020-08-01)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
by: Peng Zeng, et al.
Published: (2020-09-01)

Predictive value of the sFlt-1/PlGF ratio for preeclampsia in twin pregnancies: a retrospective study
by: Satoshi Shinohara, et al.
Published: (2021-10-01)

Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: <it>FLT3 ITD sustains high levels of DUSP6 expression</it>
by: Arora Deepika, et al.
Published: (2012-07-01)

The Role of the Aryl Hydrocarbon Receptor in Vascular Factors Related to Preeclampsia in a Smoking Mouse Model
by: Ho-Yeon Kim, et al.
Published: (2024-01-01)

Abl family kinases in development and disease /
by: Koleske, Anthony J.
Published: (2006)

Small Molecule Induced FLT3 Degradation
by: Sun-Young Han
Published: (2022-03-01)

The Important Role of FLT3-L in Ex Vivo Expansion of Hematopoietic Stem Cells following Co-Culture with Mesenchymal Stem Cells
by: Farhad Oubari, et al.
Published: (2015-07-01)